Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action;Wirkmechanismen der Vasokonstriktiven Therapie der Ö sophagusvarizenblutung

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 10, 2003, Pages 1001-1016

  Döhler, Klaus D ^a,e   Walker, S ^b   Mentz, P ^a   Forssmann, K ^a,c   Staritz, M ^d  

^a IPF PHARMACEUTICALS GMBH   (Germany)

^b Krankenhaus Bietigheim   (Germany)

^c Baxter Deutschland GmbH   (Germany)

^d Medizinische Klinik   (Germany)

^e NONE   (Germany)

Author keywords

Central hypovolaemia; Esophageal varices bleeding; Hepatorenal syndrome; Hyperdynamic circulation; Liver cirrhosis; Octreotide; Pharmacological mechanisms; Portal hypertension; Somatostatin; Terlipressin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DRUG DERIVATIVE; LYPRESSIN; OCTREOTIDE; RENIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ADRENERGIC SYSTEM; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EMERGENCY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; HYPOVOLEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER PERFUSION; MORTALITY; ORGAN PERFUSION; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD PRESSURE; PORTOCAVAL SHUNT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SPLANCHNIC BLOOD FLOW; SURVIVAL RATE; SYNDROME DELINEATION; TACHYPHYLAXIS; VASOCONSTRICTION;

CLINICAL TRIALS; DRUG APPROVAL; EMERGENCIES; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LYSINE VASOPRESSIN; OCTREOTIDE; SOMATOSTATIN; SPLANCHNIC CIRCULATION; VASOCONSTRICTOR AGENTS;

EID: 0242300249     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42931     Document Type: Review

References (185)

1. Henriksen JH, Bendtsen F, Sorensen TI et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97: 1506-1513
2. Henriksen JH, Moller S, Schifter S et al. Increased arterial compliance in decompensated cirrhosis. J Hepatol 1999; 31: 712-718
3. Henriksen JH, Moller S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In: Epstein M (Hrsg). The kidney in liver disease. 4th ed. Philadelphia: Hanley and Belfus, 1996: 241-258
4. Moller S, Sondergaard L, Mogelvang J et al. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-478
5. Moller S, Hansen EF, Becker U et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-59
6. Moller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001; 15: 94-106
7. Bosch J, Pizcueta MP, Fernandez M et al. Hepatic splanchnic and systemic haemodynamic abnormalities in portal hypertension. Baillière's Clin Gastroenterol 1992; 6: 425-436
8. Panes J, Pique JM, Bordas JM et al. Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology 1994; 19: 55-60
9. Lee WC, Lin HC, Yang YY et al. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. Am J Gastroenterol 2001; 96: 1210-1216
10. Moller S, Bendtsen F, Henriksen JH. Effect of beta-adrenergic blockade on elevated arterial compliance and low systemic vascular resistance in cirrhosis. Scand J Gastroenterol 2001; 36: 653-657
11. Jalan R, Forrest EH, Redhead DN et al. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-670
12. Sacerdoti D, Bolognesi M, Merkel C et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17: 219-224
13. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-170
14. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In: Bosch J and Groszmann RJ (Hrsg). Portal Hypertension. Pathophysiology and Treatment. Oxford: Blackwell, 1994: 17-26
15. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157
16. Bhasin DK, Malhi NJ. Variceal bleeding and portal hypertension: much to learn, much to explore. Endoscopy 2002; 34: 119-128
17. Bosch J. The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. P R Health Sci J 2000; 19: 57-67
18. D'Amico G, Pietrosi G, Tarantino I et al. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients (Cochrane Review). Cochrane Database Syst Rev 2002; CD002233
19. Escorsell A, Ruiz dA, Planas R et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000; 32: 471-476
20. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2001; CD002147
21. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000; 46 (Suppl 3-4): III1-III15
22. Lebrec D. A discussion of how terlipressin limits mortality in cases of bleeding oesophageal varices. Eur J Gastroenterol Hepatol 1998; 10: 549-552
23. Levacher S, Letoumelin P, Pateron D et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-868
24. Moreau R, Asselah T, Condat B et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-94
25. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-930
26. De Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846-852
27. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505
28. Boldys H, Romanczyk T, Hartleb M et al. Short-term effects of variceal sclerotherapy on portal hypertensive gastropathy. Endoscopy 1996; 28: 735-739
29. D'Amico G, Montalbano L, Traina M et al. Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology 1990; 99: 1558-1564
30. Hou MC, Lin HC, Chen CH et al. Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: an endoscopic observation. Gastrointest Endosc 1995; 42: 139-144
31. Moller S. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Dan Med Bull 1998; 45: 1-14
32. Tanoue K, Hashizume M, Wada H et al. Effects of endoscopic injection sclerotherapy on portal hypertensive gastropathy: a prospective study. Gastrointest Endosc 1992; 38: 582-585
33. Yoshikawa I, Murata I, Nakano S et al. Effects of endoscopic variceal ligation on portal hypertensive gastropathy and gastric mucosal blood flow. Am J Gastroenterol 1998; 93: 71-74
34. Lo GH, Lai KH, Cheng JS et al. The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 2001; 53: 579-584
35. Kehne S, Hughes FA, Gompertz ML. The use of surgical pituitrin in the control of esophageal varix bleeding. Surgery 1956; 39: 917-925
36. Spech HJ, Liehr H. Konservative Therapie. In: Siewert JR, Blum AL, Fahrtmann EH et al (Hrsg). Interdisziplinäre Gastroenterologie. Notfalltherapie. Berlin/Heidelberg/New York: Springer Verlag, 1982: 120
37. Heldwein W. Endoskopische Therapie. In: Zoller WG and Gross M (Hrsg). Ösophagusvarizenblutungen, neue therapeutische Strategien. Basel: Karger, 1998: 10-33
38. Aronsen KF, Bjorkman I, Lindstrom K et al. The mechanism of lysine-vasopressin hemostasis in bleeding esophageal varices. Acta Chir Scand 1979; 145: 231-234
39. Cestari R, Braga M, Missale G et al. Haemodynamic effect of triglycyl-lysine-vasopressin (glypressin) on intravascular oesophageal variceal pressure in patients with cirrhosis. A randomized placebo controlled trial. J Hepatol 1990; 10: 205-210
40. Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993; 17: 828-832
41. Chiu WK, Sheen IS, Liaw YF. A controlled study of glypressin versus vasopressin in the control of bleeding from esophageal varices. J Gastroenterol-Hepatol 1990; 5: 106-111
42. D'Amico G, Traina M, Vizzini G et al. Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Liver Study Group of V. Cervello Hospital. J Hepatol 1994; 20: 206-212
43. Desaint B, Florent C, Levy VG. A randomized trial of triglycyl-lysine vasopressin versus lysine vasopressin in active cirrhotic variceal hemorrhage. In: Lebrec D and Blei AT (Hrsg). Vasopressin Analogs and Portal Hypertension. Paris: Libbey Eurotext, 1987: 155-157
44. Freeman JG, Cobden I, Lishman AH et al. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet 1982; 2: 66-68
45. Freeman JG, Barton JR, Record CO. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Aliment Pharmacol Ther 1988; 2: 361-367
46. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989; 11: 58-60
47. Hansen EF, Strandberg C, Hojgaard L et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J Hepatol 1999; 30: 503-510
48. Hansen EF, Bendtsen F, Brinch K et al. Endoscopic Doppler ultrasound for measurement of azygos blood flow. Validation against thermo-dilution and assessment of pharmacological effects of terlipressin in portal hypertension. Scand J Gastroenterol 2001; 36: 318-325
49. Heinemann A, Stauber RE. Effect of terlipressin on in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1996; 24: 739-746
50. Huang YT, Tsai JF, Lin HC et al. Hemodynamic effects of acute tetrandrine and terlipressin administration on portal hypertensive rats. Can J Physiol Pharmacol 1997; 75: 1220-1225
51. Klein CP. Der Einfluss von Glycylpressin auf Leberzirrhosen. In: Paquet KJ, Denck H, Zöckler CE (Hrsg). Die Ösophagusvarizenblutung, Diagnose und Theapie. Bad Oeynhausen: TM Verlag, 1984: 67-68
52. Kohaus HM, Kautz G, Spiegel M et al. Die Sauerstoffspannung in der Leber nach Applikation von Glycylpressin beim Hund. In: Sutor AH (Hrsg). Vasopressin Analogues and Haemostasis. Stuttgart: Schattauer Verlag, 1981: 126-129
53. Kohaus HM, Kautz G, Holzgreve A. Die unterstützende Therapie der akuten Ösophagusvarizenblutung mit dem Vasopressinderivat: Triglycyl-Lysin-Vasopressin (TGLVP). Intensivmed 1982; 19: 30-33
54. Merkel C, Gatta A, Bolognesi M et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988; 33: 1103-1109
55. Nevens F, Van Steenbergen W, Yap SH et al. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996; 38: 129-134
56. Soderlund C, Magnusson I, Torngren S et al. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990; 25: 622-630
57. Staritz M, Rambow A, Meyer zum Buschenfelde KH. [Effect of glycylpressin on pressure in esophageal varices in patients with liver cirrhosis and previous hemorrhaging varices]. Dtsch Med Wochenschr 1987; 112: 1292-1295
58. Walker S, Stiehl A, Raedsch R et al. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology 1986; 6: 112-115
59. Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices - final report of a placebo-controlled, double-blind study. Z Gastroenterol 1996; 34: 692-698
60. Walker S, Kreichgauer HP, Bode JC. Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study. Hepatology 1992; 15: 1023-1030
61. Bruha R, Marecek Z, Spicak J et al. Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology 2002; 49: 1161-1166
62. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997; 26: 1229-1234
63. Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570
64. Le Moine O, el Nawar A, Jagodzinski R et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998; 61: 268-270
65. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48
66. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948
67. Colle I, Durand F, Pessione F et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-888
68. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-158
69. Pauwels A, Florent C, Desaint B et al. [Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices]. Gastroenterol Clin Biol 1994; 18: 388-389
70. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-354
71. Escorsell A, Bandi JC, Moitinho E et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-627
72. Dimitrov A. [The use of the vasoconstrictor hemostatic Remestyp in surgical obstetrics]. Akush Ginekol (Sofia) 1999; 38: 58-60
73. Eyraud D, Brabant S, Nathalie D et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 1999; 88: 980-984
74. Garner WL, Thomson PD, Moore NP et al. Effect of triglycyl-lysine-vasopressin on skin blood flow and blood loss during wound excision in patients with burns. J Burn Care Rehabil 1993; 14: 458-460
75. Jelinek J, Huvar I, Roztocil A et al. [Hemostasis using vasopressin analogs during conization of the uterine cervix and minor vaginal operations]. Ceska Gynekol 1997; 62: 142-144
76. Sönmez G. Zur Beeinflussung von Uteruskontraktion, Blutbild und Laktation bei Wöchnerinnen durch postpartale Applikation von Terlipressin. Dissertation. Medizinische Hochschule Hannover, 1999
77. O'Brian A, Clapp L, Singer M. Terlipressin for norepinephrine-resistent septic shock. Lancet 2002; 359: 1209-1210
78. Denck H, Paquet KJ. Zur Behandlung der Ösophagusvarizenblutung mit Glypressin (Glycylpressin). In: Paquet KJ and Denck H (Hrsg). Portale Hypertension. Basel: Karger, 1982: 55-57
79. Moreau R, Cailmail S, Valla D et al. Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats. Aliment Pharmacol Ther 1997; 11: 993-997
80. Schneider B. Veränderungen des transhepatisch gemessenen Pfortaderdrucks unter Terlipressin, Terlipressin und Glyceroltrinitrat und Somatostatin beim Leberzirrhotiker mit Pfortaderhochdruck und Zustand nach Ösophagusvarizenblutung. In: Paquet KJ, Schölmerich J (Hrsg). Pfortaderhochdruck. Basel: Karger, 1994: 408-411
81. Blei AT, Groszmann RJ, Gusberg R et al. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci 1980; 25: 688-694
82. Oberti F, Veal N, Kaassis M et al. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J Hepatol 1998; 29: 103-111
83. Moller S, Brinch K, Henriksen JH et al. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997; 26: 1026-1033
84. McCormick PA, Jenkins SA, McIntyre N et al. Why portal hypertensive varices bleed and bleed: a hypothesis. Gut 1995; 36: 100-103
85. Decaux G, Prospert F, Namias B et al. Hyperuricemia as a clue for central diabetes insipidus (lack of Vl effect) in the differential diagnosis of polydipsia. Am J Med 1997; 103: 376-382
86. Duhamel C, Mauillon J, Berkelmans I et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 2000; 95: 2984-2985
87. Keller U, Sonnenberg GE, Kayasseh L et al. [Dosage dependence of the effect of somatostatin on human splanchnic blood flow]. Schweiz Med Wochenschr 1979; 109: 595-596
88. Avgerinos A, Armonis A, Rekoumis G et al. The effect of somatostatin and octreotide on intravascular oesophageal variceal pressure in patients with cirrhosis. J Hepatol 1995; 22: 379-380
89. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 518-525
90. Cirera I, Feu F, Luca A et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995; 22: 106-111
91. Eriksson LS, Law DH, Sato Y et al. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis. Clin Physiol 1984; 4: 5-11
92. Hanisch E, Doertenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices. Pharmacology and rationale for use. Drugs 1992; 44 (Suppl 2): 24-35
93. Kleber G, Sauerbruch T, Fischer G et al. Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. Gut 1988; 29: 153-156
94. Mastai R, Bosch J, Navasa M. Effect of a continuous infusion and bolus injections of somatostatin (SMT) on azygos blood flow and hepatic and systemic hemodynamics in patients with liver cirrhosis. J Hepatol 1986; 3 (Suppi 1): S53
95. Merkel C, Gatta A, Zuin R et al. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985; 32: 92-98
96. Nevens F, Sprengers D, Fevery J. The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis. J Hepatol 1994; 20: 27-31
97. Sonnenberg A, West C. Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver. Gut 1983; 24: 148-153
98. Kleber G, Sauerbruch T, Fischer G et al. Erhöhung des transmuralen Ösophagusvarizendrucks unter Somatostatin-, nicht unter Placebo-Infusion. Z Gastroenterol 1987; 25: 40
99. Nishida H, Giostra E, Spahr L et al. Validation of color Doppler EUS for azygos blood flow measurement in patients with cirrhosis: application to the acute hemodynamic effects of somatostatin, octreotide, or placebo. Gastrointest Endosc 2001; 54: 24-30
100. Escorsell A, Bandi JC, Andreu V et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 161-169
101. Avgerinos A, Klonis C, Rekoumis G et al. A prospective randomized trial comparing somatostatin, balloon tamponade and the combination of both methods in the management of acute variceal haemorrhage. J Hepatol 1991; 13: 78-83
102. Jaramillo JL, de la MM, Mino G et al. Somatostatin versus Sengstaken balloon tamponade for primary haemostasia of bleeding esophageal varices. A randomized pilot study. J Hepatol 1991; 12: 100-105
103. Gotzsche PC, Gjorup I, Bonnen H et al. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995; 310: 1495-1498
104. Gotzsche PC, Gjorup IE, Bonnen H et al. [Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]. Ugeskr Laeger 1996; 158: 2393-2396
105. Valenzuela JE, Schubert T, Fogel MR et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10: 958-961
106. Avgerinos A, Nevens F, Raptis S et al. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350: 1495-1499
107. Burroughs AK, McCormick PA, Hughes MD et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990; 99: 1388-1395
108. Avgerinos A, Viazis N, Vlachogiannakos J et al. Two different doses and duration schedules of somatostatin - 14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study. J Hepatol 2000; 32: 171-172
109. Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software
110. Bosch J, Lebrec D, Jenkins SA. Development of analogues: successes and failures. Scand J Gastroenterol Suppl 1998; 226: 3-13
111. Bosch J, Kravetz D, Mastai R et al. Effects of somatostatin in patients with portal hypertension. Horm Res 1988; 29: 99-102
112. Burroughs AK. Pharmacological treatment of acute variceal bleeding. Digestion 1998; 59 (Suppl 2): 28-36
113. Moitinho E, Planas R, Banares R et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712-718
114. De Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001; 5: 645-663
115. Franco-Cereceda A, Bengtsson L, Lundberg JM. Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal polypeptide and somatostatin on the human right atrium in vitro. Eur J Pharmacol 1987; 134: 69-76
116. Hou ZY, Lin CI, Chiu TH et al. Somatostatin effects in isolated human atrial fibres. J Mol Cell Cardiol 1987; 19: 177-185
117. Gines A, Salmeron JM, Gines P et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992; 103: 1868-1874
118. Albillos A, Colombato LA, Lee FY et al. Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104: 575-579
119. Huang YT, Wu HL, Chern JW et al. Hemodynamic effects of 8-day DL-028 and octreotide administration in rats with portal hypertension. Scand J Gastroenterol 1998; 33: 1303-1309
120. Jenkins SA, Baxter JN, Corbett WA et al. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985; 72: 1009-1012
121. Jenkins SA, Baxter JN, Corbett WA et al. The effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the cirrhotic rat. Br J Surg 1985; 72: 864-867
122. Eriksson LS, Hagenfeldt L, Mutt V et al. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides 1989; 10: 481-484
123. Schiedermaier P, Brensing KA, Goke B et al. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Digestion 1999; 60: 132-140
124. Besson I, Ingrand P, Person B et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555-560
125. Burroughs AK. For the International Octreotide Varices Group: Double-blind RCT of 5-day octreotide versus placebo associated with sclerotherapy for trial failures. Hepatology 1996; 24: 352A
126. D'Amico G, Politi F, Morabito A et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28: 1206-1214
127. Lin HC, Yang YY, Hou MC et al. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. Scand J Gastroenterol 2002; 37: 482-487
128. Sung JJ, Chung SC, Yung MY et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346: 1666-1669
129. Zironi G, Rossi C, Siringo S et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver 1996; 16: 225-234
130. Eriksson LS, Brundin T, Soderlund C et al. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987; 22: 919-925
131. Albillos A, Rossi I, Iborra J et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21: 88-94
132. Ludwig D, Schadel S, Bruning A et al. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci 2000; 45: 1019-1027
133. McCormick PA, Biagini MR, Dick R et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16: 1180-1186
134. De Franchis R, Pascal JP, Ancona E et al. Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992; 15: 256-261
135. McKee R. A study of octreotide in oesophageal varices. Digestion 1990; 45 (Suppl 1): 60-64
136. Hwang SJ, Lin HC, Chang CF et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992; 16: 320-325
137. Silvain C, Carpentier S, Sautereau D et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993; 18: 61-65
138. Jenkins SA, Shields R, Davies M et al. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997; 41: 526-533
139. Poo JL, Bosques F, Garduno R et al. Octreotide versus emergency sclerotherapy in acute variceal hemorrhage in liver cirrhosis. Gastroenterology 1996; 110: 1297A
140. Sung JJ, Chung SC, Lai CW et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342: 637-641
141. El-Jackie A, Rowaisha I, Waked I et al. Octreotide vs. Sclerotherapy in the control of acute variceal bleeding in schistosomal portal hypertension: A randomized trial. Hepatology 1998; 28: 533A
142. Kravetz D. Group for the Study of Portal Hypertension. Octreotide vs. sclerotherapy in the treatment of acute variceal bleeding. Hepatology 1996; 4 (Suppl 24): 206A
143. Burroughs AK, Patch D. Therapeutic benefit of vaso-active drugs for acute variceal bleeding: a real pharmacological effect, or a side-effect of definitions in trials? Hepatology 1996; 24: 737-739
144. Burroughs AK, Planas R, Svoboda P. Optimizing emergency care of upper gastrointestinal bleeding in cirrhotic patients. Scand J Gastroenterol Suppl 1998; 226: 14-24
145. Goulis J, Burroughs AK. Role of vasoactive drugs in the treatment of bleeding oesophageal varices. Digestion 1999; 60 (Suppl 3): 25-34
146. Corley DA, Cello JP, Adkisson W et al. Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 2001; 120: 946-954
147. Ottesen LH, Flyvbjerg A, Moller S et al. The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. Aliment Pharmacol Ther 1998; 12: 657-665
148. Primignani M, Carpinelli L, Vazzoler MC et al. Shortterm effect of octreotide on intraoesophageal varices pressure: a double-blind placebo-controlled study. Eur J Gastroenterol Hepatol 1994; 6: 1027-1031
149. Yang YY, Lin HC, Huang YT et al. Adaptive vasodilatory response after octreotide treatment. Am J Physiol Gastrointest Liver Physiol 2001; 281: G117-G123
150. Jenkins SA, Baxter JN, Snowden S. The effects of somatostatin and SMS 201-995 on hepatic and systemic haemodynamics in patients with cirrhosis and portal hypertension. Fibrinolysis 1988; 2: 48-50
151. McKee RK, Pringle SD, Garden OJ. SMS 201-995 in the management of variceal bleeding. Gut 1989; 28: 1380A
152. Wahren J, Eriksson LS. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol Suppl 1986; 119: 103-108
153. Schiedermaier P, Goke B, Sauerbruch T. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS. Am J Gastroenterol 2001; 96: 2218-2224
154. Londong W, Angerer M, Kutz K et al. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96: 713-722
155. Aboud RW, Connolly C, McCormick PA et al. Vascular actions of octreotide in the portal hypertensive rat. Br J Pharmacol 1997; 122: 698-702
156. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992; 262: G274-G277
157. Reikeras O, Gunnes P. Effects of high doses of insulin on systemic haemodynamics and regional blood flows in dogs. Clin Physiol 1986; 6: 129-138
158. Rozsa Z, Varro V. Mechanism of "substance P": on mesenteric blood flow; interactions with opioid peptides. Neuropeptides 1987; 10: 275-290
159. Huang YT, Tsai JF, Liu TB et al. Chronic administration of octreotide increases vascular responsiveness in rats with portal hypertension. Clin Sci (Lond) 1996; 91: 601-606
160. Hanisch E, Strasse R, Wenzel M et al. [In vitro contractility behavior of portal veins in normal rats and in rats with liver cirrhosis-effect of calcium antagonists and octreotide]. Z Gastroenterol 1993; 31: 600-604
161. Heller J, Schepke M, Neef M et al. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002; im Druck
162. Uriz J, Gines P, Ortega R et al. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002; 36: 349-355
163. Li J, Dai Z, Cui W et al. A quantitative study on vascular angiotensin II receptors in rats with portal hypertension. J Tongji Med Univ 1997; 17: 235-238
164. Sitzmann JV, Wu Y, Aguilera G et al. Loss of angiotensin-II receptors in portal hypertensive rabbits. Hepatology 1995; 22: 559-564
165. Jenkins SA, Nott DM, Baxter JN. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. HPB Surg 1998; 11: 13-21
166. Consensus statement: benefits versus risks of medical therapy for acromegaly. Acromegaly Therapy Consensus Development Panel. Am J Med 1994; 97: 468-473
167. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988; 9: 417-436
168. Fredenrich A, Sosset C, Bernard JL et al. Acute pancreatitis after short-term octreotide. Lancet 1991; 338: 52-53
169. Sadoul JL, Benchimol D, Thyss A et al. Acute pancreatitis following octreotide withdrawal. Am J Med 1991; 90: 763-764
170. Sternlieb JM, Aronchick CA, Retig JN et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87: 1561-1566
171. Lin HC, Hou MC, Lee WC et al. Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis. Am J Gastroenterol 1999; 94: 1012-1017
172. Lin CI, Wei J, Cheng KK et al. Electropharmacological effects of sandostatin in human atrial fibers. Int J Cardiol 1991; 31: 313-318
173. McCormick PA, Chin J, Greenslade L et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995; 21: 1255-1260
174. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M et al. Effects of a
175. Camilleri M. Effects of somatostatin analogues on human gastrointestinal motility. Digestion 1996; 57 (Suppl 1): 90-92
176. Cales P, Masliah C, Bernard B et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 2001; 344: 23-28
177. Mottet C, Sieber C, Nauer A et al. Hemodynamic effects of the somatostatin analog lanreotide in humans. Placebo-controlled, cross-over dose-ranging echo-Doppler study. Hepatology 1998; 27: 920-925
178. Schiedermaier P, Harrison P, Arthur M et al. Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis. Digestion 2002; 65: 56-60
179. De Franchis R. Longer treatment with vasoactive drugs to prevent early variceal rebleeding in cirrhosis. Eur J Gastroenterol Hepatol 1998; 10: 1041-1044
180. De Franchis R. Emerging strategies in the management of upper gastrointestinal bleeding. Digestion 1999; 60 (Suppl 3): 17-24
181. De Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 439-455
182. Gross M, Zoller WG. Medikamentöse Therapie der akuten Ösophagusvarizenblutung - Ergänzung oder Alternative zur endoskopischen Therapie? In: Zoller WG, Gross M (Hrsg). Ö sophagusvarizenblutungen - Neue therapeutische Strategien. Basel: Karger, 1998: 34
183. Gross M, Schiemann U, Muhlhofer A et al. Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy 2001; 33: 737-746
184. Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995; 109: 1289-1294
185. Moreau R, Barriere E, Tazi KA et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology 2002; 36: 1070-1078